Komodo Health Acquires Breakaway Partners to Improve Patient Access to Effective Therapies
Komodo Health has acquired Breakaway Partners, a market access software company for the life sciences industry. This acquisition brings together Komodo’s Healthcare Map and software with Breakaway Partners’ formulary data, policy criteria, and analytics platform to create the industry’s first enterprise market access solution suite based on a comprehensive, real-time view of real-world outcomes and costs.
As healthcare payers and providers continue the shift to value-based payment models, which incentivize the use of the most effective therapies, the market access analytics field has become critical to determine restrictions, reimbursement levels, and coverage decisions. Breakaway Partners’ software solutions track formulary changes, medical and pharmacy criteria, and payer coverage—in real time and across geographies—to inform market landscape strategies for new and existing therapies.
“Together, Komodo and Breakaway are pairing the largest map of real-world evidence with real-time market access insights,” said Komodo Health Co-founder and CEO Arif Nathoo, MD. “Breakaway is a pioneer in using technology to provide market access teams real-time insights on policy decisions. We couldn’t be more thrilled to add their solutions and expertise to further our mission of reducing the burden of disease.”
“Gaps in access lead to gaps in care delivery,” added Web Sun, president and co-founder of Komodo Health. “In a value-driven world, payers, providers, and life sciences companies need faster, more complete insights to bridge the gap between new breakthroughs, the potential impact on patient outcomes, and formulary decisions. With this acquisition, we will be delivering solutions that encompass a real-time, comprehensive view of the entire market access landscape.”
Historically, market access decisions have been based on expensive, manual, and time-intensive analyses of aggregated formulary and policy criteria. The resulting insights were often out-of-date and incomplete, and they lacked visibility into patient outcomes. Now, through a single software interface, it will be possible to quickly understand and prioritize patient access with insights rooted in the current landscape of existing restrictions, as well as the real-world experience of individual patients.
Read the original press release here.
See additional coverage in: